If you have been given an outpatient appointment at the hospitals and are unable to attend for whatever reason you can use the form below.
It is really important that you let us know of any changes as soon as possible. This means we can offer the original appointment to another patient.
Please complete the form below with your contact details and as much information as possible. You can find most of the information we need on your appointment letter.
If you have any problems using this form, please call the number on your appointment letter and we will do our best to help you. You will receive a response from us so you know it has been received and actioned.
If you wish to change the date and time of your appointment you, you can click the re-book option and state any dates that are not suitable for you, or you can contact us using the number on your appointment letter.
Rita Arya Principal Investigator
Tel: 01925 275211
Lindsay Roughley Research Midwife
Tel: 01925 275211
Rachel Crone Research Midwife
Tel: 01925 275514
This study aims to find out whether, in women with pre-eclampsia between 34 and 37 weeks of pregnancy, planned early birth cause fewer complications for the mother and or baby, compared to waiting until 37 weeks
Pre-eclampsia can be a serious condition for both mother and baby. Most women with pre-eclampsia make a full recovery and their babies are healthy. However, pre-eclampsia can cause a sudden, rapid rise in blood pressure and in severe cases cause fits, strokes, multiple organ failure and very rarely death. Babies whose mothers have pre-eclampsia tend to be smaller and are more likely to be born early. The cause of pre-eclampsia is unknown.
This study aims to find out whether, in women with pre-eclampsia between 34 and 37 weeks of pregnancy, planned early birth cause fewer complications for the mother and or baby, compared to waiting until 37 weeks. The study may help improve the care of women with pre-eclampsia in the future.
A multi-centre double-blind placebo-controlled randomised trial of a combination of methotrexate and gefitinib versus methotrexate and placebo alone as a treatment for ectopic pregnancy with a mechanistic study.
328 participants (164 participants per group) and 30 randomised patients for the mechanistic study (Edinburgh only).
To assess the effectiveness of a combination of methotrexate (MTX) and gefitinib against MTX alone in terms of the need for surgical intervention for ectopic pregnancy.
Trial website: www.trials.bham.ac.uk/GEM3
The ALIFE2 trial is a research trial to investigate whether anti-coagulant (blood thinning) treatment reduces the risk of miscarriage in women with inherited thrombophilia
The ALIFE2 trial is a research trial to investigate whether anti-coagulant (blood thinning) treatment reduces the risk of miscarriage in women with inherited thrombophilia (blood that has a tendency to clot more than normal).We are trying to understand the reasons for and improve treatment for women with recurrent miscarriage.
If you can answer yes to the three questions below you may be able to take part the ALIFE2 trial.
1. Have you had two or more miscarriages?
2. Are you aged 18 to 42 years?
3. Are you trying for a baby but are not pregnant?
If you were to take part in this trial you will be randomly assigned together the trial treatment or standard care.
What do I have to do if I am interested?
If you wish to participate or would like more information please contact the research midwives, Rachel and Lindsay on:
01925 275211 / 01925 275514
This project was funded by the National Institute for Health Research, Research for Patient Benefit –
RfPB (project number PB-PG-101332011).
CERCLAGE SUTURE TYPE FOR AN INSUFFICIENT CERVIX AND ITS EFFECT ON HEALTH OUTCOMES
For more information, contact the Warrington research midwives or email: firstname.lastname@example.org
to Evaluate urSodeoxycholic Acid (UDCA) in improving perinatal outcomes
Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis (OC) is a liver disorder which occurs during pregnancy. It affects 1 in 150 pregnancies each year in the UK.
At the moment not all women in the UK receive the same treatment for ICP: some doctors prescribe UCDA and some do not. This is because doctors haven’t got absolute proof to be sure of the best treatment to use. We need a large clinical study to see whether UCDA helps protect babies or not. At the end of the study, we hope to be able to give clear and definitive guidance for doctors treating this condition.
For more information, click on the links or contact the Warrington research midwives.
The aim of this study is to develop earlier and safer ways of detecting problems in pregnancy.
Research has shown that it may be possible to use a simple blood test taken from the mother early in pregnancy to gather information about the health of the baby and predict certain complications of pregnancy. This will do this by testing the baby’s genes and other substances in the maternal blood.
PAGE involves a more detailed look at the baby's DNA - capable of picking up smaller changes.
A prospective evaluation of accidental awareness under general anaesthesia in obstetric surgery patients
Only women who have a general anaesthetic for a surgical procedure related to pregnancy may participate in this study. Whilst in hospital they will be asked a short series of questions about what they remember about there general anaesthetic. They will also receive a telephone call at around 30 days after the anaesthetic and asked a further short series of questions. Depending on the responses we may ask to call again occasionally over the following 12 months to ask further questions about whether they are experiencing any distress related to these memories.
We have taken part in the following studies are currently awaiting the result
To find out more about them click here.